Center of Excellence in Higher Education
The First Private University in Bangladesh

Dr. Mohammad Burhan Uddin

Full Time Faculty
Assistant Professor

PhD: University of Louisiana at Monroe, USA
MPharm: Jahangirnagar University, Bangladesh

Phone: +880-2-55668200 Ext: 6268
Email: mohammad.uddin13@northsouth.edu
Office: SAC-1015

Curriculum Vitae

Mohammad Burhan Uddin obtained his PhD in Pharmacology from the University of Louisiana at Monroe, USA in 2018. He joined North South University as an assistant professor in 2023. His research interest is focused on exploring the roles of RNA post-transcriptional modifications on carcinogenesis and development of cancer drug resistance. He has gathered extensive experience working as a research scientist in various prestigious organizations including USFDA and University of Kentucky School of Medicine.

Number of Citations: 850+

  1. Uddin MB, Wang Z, Yang C. Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities. Advanced Science, 2024; 12(4): 12, 2403936. doi: 10.1002/advs.202403936.
  2. Wang Z*, Uddin MB*, Wang PS, Liu Z, Barzideh D, Yang C. Up-regulation of RNA m6A methyltransferase like-3 expression contributes to arsenic and benzo[a]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis. Toxicology and Applied Pharmacology, 2023; 481: 116764. doi: 10.1016/j.taap.2023.116764.                                                                          *Co-first authors
  3. Roy T, Boateng ST, Uddin MB, Mbeumi SB, Yadav RK, Boch CM, Folahan JT, Siwe-Noundou X, Walker A, King JAC, Buerger C, Huang S, Chamcheu JC. The PI3K-Akt-mTOR and associated signaling pathways as molecular drivers of immune-mediated inflammatory skin diseases: update on therapeutic strategy using natural and synthetic compounds. Cells, 2023; 12(12): 1671. doi: 10.3390/cells12121671.
  4. Uddin MB, Roy KR, Hill RA, Roy SC, Gu X, Li L, Zhang Q-J, You Z, Liu YY. p53 Missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection. Experimental Cell Research, 2022; 417(1): 113210. doi: 10.1016/j.yexcr.2022.113210.
  5. Wang Z*, Uddin MB*, Xie J, Tao H, Zeidler-Erdely PC, Kondo K, Yang C. Chronic Hexavalent Chromium Exposure Up-regulates the RNA Methyltransferase METTL3 Expression to Promote Cell Transformation, Cancer Stem Cell-like Property and Tumorigenesis. Toxicological Sciences, 2022; 187(1): 51-61. doi: 10.1093/toxsci/kfac023.                                          *Co-first authors
  6. Fan T W-M, Daneshmandi S, Cassel TA, Uddin MB, Sledziona J, Thompson PT, Lin P, Higashi RM, Lane AN. Polarization and beta-glucan reprogram immunomodulatory metabolism in human macrophages and ex vivo in lung cancer tissues. Journal of Immunology, 2022; 209(9): 1674-1690. doi: 10.4049/jimmunol.2200178.
  7. Uddin MB, Wang Z, Yang C. The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis. Molecular Cancer, 2021; 20(1):61. doi: 10.1186/s12943-021-01356-0.
  8. Uddin MB, Wang Z, Yang C. Dysregulations of functional RNA Modifications in Cancer, Cancer Stemness and Cancer Therapeutics. Theranostics, 2020; 10(7): 3164-3189. doi: 10.7150/thno.41687.
  9. Uddin MB, Roy KR, Hosain SB, Khiste SK, Hill RA, Jois SD, Zhao Y, Tackett AJ, Liu YY. An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochemical Pharmacology, 2019; 160, 134-145. doi: 10.1016/j.bcp.2018.12.014.
  10. Roy KR, Uddin MB, Roy SC, Hill RA, Marshall J, Li Y-T, Chamcheu JC, Lu H, Liu YY. Gb3-cSrc Complex in glycosphingolipid-enriched microdomains attributes to the expression of p53 mutant protein and cancer drug resistance via β-Catenin activated RNA-Methylation. FASEB BioAdvances, 2020, 2(11): 653–667. doi: 10.1096/fba.2020-00044.
  11. Hosain SB, Khiste SK, Uddin MB, Vorubindi V, Ingram C, Zhang S, Hill RA, Gu X, Liu YY. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells. Oncotarget, 2016, 7(37), 60575- 60592. doi: 10.18632/oncotarget.11169.
  12. Chamcheu JC, Roy T, Uddin MB, Mbeumi SB, Chamcheu RCN, Walker AL, Liu YY, Huang S. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Cells, 2019, 8, 803. doi: 10.3390/cells8080803.
  13. Khiste SK, Liu Z, Roy KR, Uddin MB, Hosain SB, Gu X, Nazzal S, Hill RA, Liu YY. Ceramide-rubusoside nanomicelles, a potential therapeutic approach to target cancers carrying p53 missense mutations. Molecular Cancer Therapeutics, 2019: p. molcanther. 0366.2019. doi: 10.1158/1535-7163.MCT-19-0366.
  14. Khiste SK, Hosain SB, Y Dong, Uddin MB, Roy KR, Hill RA, Z Liu, Liu YY. Incorporation of fluorescence ceramide-based HPLC assay for rapidly and efficiently assessing glucosylceramide synthase In Vivo. Scientific Reports, 2017, 7. doi: 10.1038/s41598-017-03320-9.
  15. Chamcheu JC, Rady I, Chamcheu RCN, Siddique AB, Bloch MB, Mbeumi SB, Babatunde AS, Uddin MB, Noubissi FK, Jurutka PW, Liu YY, Spiegelman V, Whitfield GK, Sayed KE. Graviola (Annona muricata) exerts anti-proliferative, anti- clonogenic and pro-apoptotic effects in human non-melanoma skin cancer UW-BCC1 and A431 cells in vitro: Involvement of hedgehog signaling. International Journal of Molecular Sciences, 2018, 19, 1791; doi: 10.3390/ijms19061791.
  16. W Alanazi, MB Uddin, S Fakhruddin, K Jackson. Recurrent insulin-induced hypoglycemia induces AngII and COX2 leading to renal (pro) renin receptor expression and oxidative stress. International Journal of Medicine, 2017, 5(1), 71-78. doi: 10.14419/ijm.v5i1.6858.
  17. Xie J, Yu J, Fan Y, Zhao X, Su J, Meng Y, Wu Y, Uddin MB, Wang C, Wang Z. Low dose lead exposure starting from puberty disrupts spermatogenesis-related gene expression and causes abnormal spermatogenesis in mouse. Toxicology and Applied Pharmacology, 2020, 393, 114942. doi: 10.1016/j.taap.2020.114942.
  18. H Imam, A Chowdhury, NU Mahbub, A Hossain, MFB Karim, MB Uddin, Sarker MM. Oxidizability assay of unfractionated plasma of patients with different plasma profile: a methodological study. Journal of Diabetes & Metabolic Disorders, 2014, 13:54. doi: 10.1186/2251-6581-13-54.
  19. I Nimmi, IA Jahan, MH Hossain, MB Uddin, MS Rana, MM Haq. A comparative study on antioxidant properties of two phyllanthus species growing in Bangladesh. Dhaka University Journal of Pharmaceutical Sciences, 2013, 11 (2), 191-197. doi: 10.3329/dujps.v11i2.14579.

Book Chapter

1. Uddin MB, Wang Z, Yang C. Role of m6A RNA modification in normal development and disease. Epitranscriptomics, 2021, Springer: 12, 267-308.

2018-19 | ORISE Fellow, US Food & Drug Administration (USFDA)

2018 | Best Graduate Student Oral Presentation, 18th Annual Student Research Symposium, University of Louisiana at Monroe

2006 | Imdad-Sitara Khan Trust Scholarship (Student of the year in the Faculty of Life Science)

2004-2008 | Jahangirnagar University Merit Scholarship 

2014-2018 | Ph.D. in Pharmacology

University of Louisiana at Monroe, USA

2009-2011 | MS in Pharmaceutical Science

Jahangirnagar University, Dhaka, Bangladesh (Distinction: 1st class 2nd position)

2004-2008 | B. Pharm (Hons)

Jahangirnagar University, Dhaka, Bangladesh (Distinction: 1st class 3rd position)

Assistant Professor | January 2023- Current

Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh.

Assistant Professor (Adjunct) | July 2022- December 2022

Department of Pharmaceutical Sciences, Independent University (IUB), Dhaka, Bangladesh.

Postdoctoral Scholar | July 2019- April 2022

Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

ORISE Postdoctoral Fellow | June 2018- May 2019

Center for Biologics Evaluation and Research (CBER), Office of Tissues and Advanced Therapies (OTAT), US FDA, Silver Spring, Maryland, USA.

Graduate Research Associate | Aug. 2014 - May 2018

College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana, USA.

Lecturer | Nov. 2013- Aug. 2014

Department of Pharmacy, Comilla University, Comilla, Bangladesh.

Lecturer | Jul. 2011- Nov. 2013

Department of Pharmacy, Primeasia University, Dhaka, Bangladesh.

 

Quality Control Officer | April 2008- Nov. 2008

Incepta Pharmaceuticals Ltd., Dhaka, Bangladesh

Biochemistry and Cell Biology

Pharmacology II

Pharmacotherapy I

Drug Regulatory Affairs

American Association of Pharmaceutical Scientists (AAPS)

American Association of Bangladeshi Pharmaceutical Scientists (AABPS)

Peer Reviewer in Journals:

BMC-Springer Nature: Journal of Translational Medicine (JTRM); Elsevier: Gene; Cell Press: Heliyon; Taylor & Francis: Cancer Biology & Therapy (CB&T); MDPI: Current Issues in Molecular Biology (CIMB), International Journal of Molecular Sciences (IJMS), Life, Molecules; Tech Science Press: Biocell

Dr. Mohammad Burhan Uddin is interested in exploring the molecular mechanisms of cancer drug resistance. His research is particularly focused on the role of RNA modification in oncogene expression and development of multidrug resistance.